CA
SGYP

Cliff Asness’s Synergy Pharmaceuticals, Inc Common Stock SGYP Stock Holding History

Cliff Asness’s Portfolio SGYP Stock Details SGYP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q3 		– Sell
-100,440
Closed -$447K – 2325
2017
Q2 		$447K Buy
100,440
+1,854
+2% +$7.64K ﹤0.01% 1934
2017
Q1 		$459K Buy
98,586
+72,646
+280% +$421K ﹤0.01% 1914
2016
Q4 		$158K Hold
25,940
– – ﹤0.01% 2177
2016
Q3 		$143K Hold
25,940
– – ﹤0.01% 2202
2016
Q2 		$99K Sell
25,940
-28,385
-52% -$96.2K ﹤0.01% 2167
2016
Q1 		$150K Sell
54,325
-22,590
-29% -$81.8K ﹤0.01% 2146
2015
Q4 		$436K Buy
76,915
+2,169
+3% +$13.2K ﹤0.01% 1922
2015
Q3 		$396K Buy
+74,746
New +$578K ﹤0.01% 1817
2014
Q3 		– Sell
-14,711
Closed -$60K – 2632
2014
Q2 		$60K Sell
14,711
-9,000
-38% -$38.2K ﹤0.01% 2488
2014
Q1 		$126K Sell
23,711
-332
-1% -$1.86K ﹤0.01% 2493
2013
Q4 		$133K Sell
24,043
-6,388
-21% -$27.5K ﹤0.01% 2489
2013
Q3 		$137K Sell
30,431
-21,801
-42% -$97.8K ﹤0.01% 2397
2013
Q2 		$223K Buy
+52,232
New +$262K ﹤0.01% 2189

Other funds holding SGYP

PC
Paulson & Co New York $2.58B AUM 68.51% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $529M AUM 337.4% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Cliff Asness's SGYP Position: Q3 2017 in Review

Cliff Asness sold out of Synergy Pharmaceuticals, Inc Common Stock (SGYP) in Q3 2017, closing a stake of 100,440 shares — an estimated $447K sold.

Cliff Asness first reported a position in SGYP in Q2 2013 and held it in 13 quarters. The position peaked at $459K in Q1 2017. 143 funds tracked by Wall St. Rank hold SGYP as of Q3 2017.

  • Cliff Asness reported no remaining Synergy Pharmaceuticals, Inc Common Stock position as of Q3 2017 after selling out during the quarter.
  • Cliff Asness sold 100,440 Synergy Pharmaceuticals, Inc Common Stock shares in Q3 2017, an estimated $447K.
  • Cliff Asness first reported a position in Synergy Pharmaceuticals, Inc Common Stock in Q2 2013 and held it in 13 quarters.
  • Cliff Asness's Synergy Pharmaceuticals, Inc Common Stock position peaked at $459K in Q1 2017.
  • 143 funds tracked by Wall St. Rank held Synergy Pharmaceuticals, Inc Common Stock as of Q3 2017.

Based on AQR Capital Management's 13F filing for Q3 2017, filed 14 Nov 2017.